CD274 and non-small cell lung carcinoma: To date, four anti-PD-1/PD-L1 monoclonal antibodies (nivolumab, pembrolizumab (anti-PD-1); atezolimumab and durvalumab (anti-PD-L1)) have been approved as 1st or 2nd line therapy for NSCLC patients with metastatic and locally advanced NSCLC respectively (12, 13).